오피오이드 사용 장애 시장 : 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global opioids use disorder market size is expected to reach USD 15.28 Billion in 2034 from USD 6.62 Billion in 2025, growing at a CAGR of 9.74 during 2026-2034.The opioids use disorder market is undergoing significant evolution as healthcare systems prioritize effective treatment strategies and harm reduction measures. Rising prevalence of opioid dependence and overdose incidents has intensified demand for advanced therapeutic interventions, including buprenorphine, methadone, and emerging non-opioid pharmacotherapies. Integrated care models combining medication-assisted treatment (MAT), behavioral therapy, and digital adherence monitoring are becoming essential for long-term recovery outcomes. Regulatory initiatives and public health campaigns are further supporting patient access to innovative therapies.

Technological and clinical advancements are expanding treatment efficacy and accessibility. Digital health platforms provide remote monitoring, predictive risk alerts, and adherence tracking, enabling personalized treatment strategies. Novel drug formulations, including extended-release and sublingual delivery systems, are improving patient compliance while reducing misuse potential. Research into non-addictive analgesics, vaccine-based interventions, and neuromodulation therapies is creating new therapeutic avenues. Healthcare providers are increasingly leveraging telemedicine and mobile health technologies to reach underserved populations and improve intervention success rates.

The future trajectory is defined by integrated public health strategies, policy support, and pharmaceutical innovation. North America remains the largest market due to high prevalence and mature treatment infrastructure, while emerging economies are gradually scaling access to evidence-based therapies. Strategic partnerships between healthcare providers, digital health innovators, and pharmaceutical companies are fostering a comprehensive ecosystem for diagnosis, treatment, and recovery support. As awareness, technology, and therapeutic options expand, the opioids use disorder market is poised to provide more effective, patient-centric solutions that address both medical and societal challenges.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Naltrexone
• Buprenorphine
• Methadone
• Others

By Route of Administration

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Indivior PLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Collegium Pharmaceutical, Inc., Alkermes Inc., Orexo AB, Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Viatris Inc. (Mylan N.V.), Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Endo International plc, Purdue Pharma L.P., Assertio Holdings, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPIOIDS USE DISORDER MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Naltrexone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Buprenorphine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Methadone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPIOIDS USE DISORDER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPIOIDS USE DISORDER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPIOIDS USE DISORDER MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OPIOIDS USE DISORDER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Indivior PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Pfizer Inc
  • 9.2.4 Collegium PharmaceuticalInc
  • 9.2.5 Alkermes Inc
  • 9.2.6 Orexo AB
  • 9.2.7 Titan PharmaceuticalsInc
  • 9.2.8 Omeros Corporation
  • 9.2.9 Camurus AB
  • 9.2.10 Hikma Pharmaceuticals PLC
  • 9.2.11 Mallinckrodt Pharmaceuticals
  • 9.2.12 Viatris Inc. (Mylan N.V.)
  • 9.2.13 Boehringer Ingelheim International GmbH
  • 9.2.14 Janssen PharmaceuticalsInc
  • 9.2.15 Sanofi S.A
  • 9.2.16 Sun Pharmaceutical Industries Ltd
  • 9.2.17 Endo International Plc
  • 9.2.18 Purdue Pharma L.P
  • 9.2.19 Assertio HoldingsInc